Figure 1.

Pathway from lead to drug candidate suitable for clinical trials. The diagram represents the complex interactions, nonlinear nature of the process, and the potential setbacks. cGMP, current Good Manufacturing Practices; GLP, Good Laboratory Practice; IND, Notice of Claimed Investigational Exemption for a New Drug; PK, pharmacokinetics.

Hefti BMC Neuroscience 2008 9(Suppl 3):S7   doi:10.1186/1471-2202-9-S3-S7